39 related articles for article (PubMed ID: 21821501)
1. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Feola M; Lombardo E; Taglieri C; Vallauri P; Piccolo S; Valle R
Med Sci Monit; 2011 Feb; 17(3):PI7-13. PubMed ID: 21358614
[TBL] [Abstract][Full Text] [Related]
2. Ischemia-modified albumin levels in patients with acute decompensated heart failure treated with dobutamine or levosimendan: IMA-HF study.
Çavuşoğlu Y; Korkmaz Ş; Demirtaş S; Gencer E; Şaşmaz H; Mutlu F; Güneş H; Mert UK; Özdemir S; Kalaycı S; Yılmaz MB
Anatol J Cardiol; 2015 Aug; 15(8):611-7. PubMed ID: 26301344
[TBL] [Abstract][Full Text] [Related]
3. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
[TBL] [Abstract][Full Text] [Related]
5. Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.
Tasal A; Demir M; Kanadasi M; Bacaksiz A; Vatankulu MA; Sahin DY; Eker RA; Bozkurt A; Acarturk E
Med Sci Monit; 2014 Feb; 20():276-82. PubMed ID: 24549281
[TBL] [Abstract][Full Text] [Related]
6. Effect of outpatient administration of levosimendan in reducing hospital readmission in patients with heart failure.
Acosta-Armas P; Medina-Gil JM; Martínez-Quintana E
Med Clin (Barc); 2023 Nov; 161(9):403-404. PubMed ID: 37598053
[No Abstract] [Full Text] [Related]
7. Repetitive ambulatory levosimendan as a bridge to heart transplantation.
de Juan Bagudá J; de Frutos F; López-Vilella R; Couto Mallón D; Guzman-Bofarull J; Blazquez-Bermejo Z; Cobo-Belaustegui M; Mitroi C; Pastor-Pérez FJ; Moliner-Abós C; Rangel-Sousa D; Díaz-Molina B; Tobar-Ruiz J; Salterain Gonzalez N; García-Pinilla JM; García-Cosío Carmena MD; Crespo-Leiro MG; Dobarro D; Almenar L; Delgado-Jiménez JF; Paredes-Galán E; González-Vílchez F; González-Costello J
Rev Esp Cardiol (Engl Ed); 2024 Apr; 77(4):290-301. PubMed ID: 37516313
[TBL] [Abstract][Full Text] [Related]
8. Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.
Najjar E; Stålhberg M; Hage C; Ottenblad E; Manouras A; Haugen Löfman I; Lund LH
ESC Heart Fail; 2018 Jun; 5(3):302-308. PubMed ID: 29469177
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Aimo A; Arzilli C; Castiglione V; Morfino P; Panichella G; Passino C; Vergaro G; Emdin M
Int J Cardiol; 2024 Jun; 405():131963. PubMed ID: 38479497
[TBL] [Abstract][Full Text] [Related]
10. Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study.
Cholley B; Bojan M; Guillon B; Besnier E; Mattei M; Levy B; Ouattara A; Tafer N; Delmas C; Tonon D; Rozec B; Fellahi JL; Lim P; Labaste F; Roubille F; Caruba T; Mauriat P;
Ann Intensive Care; 2023 Sep; 13(1):94. PubMed ID: 37770809
[No Abstract] [Full Text] [Related]
11. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
[TBL] [Abstract][Full Text] [Related]
12. [Levosimendan in heart failure].
Scelsi L; Campana C; Ghio S; Monti L; Opasich C; De Feo S; Cobelli F; Orlandi M; Di Pasquale G; Tavazzi L
Recenti Prog Med; 2004; 95(7-8):376-83. PubMed ID: 15303549
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
14. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
[TBL] [Abstract][Full Text] [Related]
15. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
